Skip to main content

Zenocutuzumab Side Effects

Applies to zenocutuzumab: intravenous solution.

General adverse events

The most common adverse events were diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions, dyspnea, rash, constipation, vomiting, abdominal pain, and edema. The most common Grade 3 or 4 laboratory abnormalities were increased gamma-glutamyl transpeptidase (GGT), decreased hemoglobin, decreased sodium, decreased platelets, increased AST, increased ALT, increased alkaline phosphatase, decreased magnesium, decreased phosphate, increased activated partial thromboplastin time (aPTT) and increased bilirubin.[Ref]

Hematologic

Immunologic

Infusion-related reactions (IRR) includes chills, IRR, nausea, cough, diarrhea, back pain, body temperature increased, dyspnea, face edema, fatigue, non-cardiac chest pain, oropharyngeal discomfort, paresthesia, pyrexia, and vomiting.[Ref]

Musculoskeletal

Metabolic

Psychiatric

Oncologic

Respiratory

Other

Renal

Cardiovascular

Dermatologic

Gastrointestinal

References

1. (2024) "Product Information. Bizengri (zenocutuzumab)." Merus US, Inc

Further information

Zenocutuzumab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.